Multiple dosing of prostaglandin F2 alpha or epinephrine on cynomolgus monkey eyes. I. Aqueous humor dynamics.
Camras C B, Podos S M, Rosenthal J S, Lee P Y, Severin C H
AI Summary
Topical PGF2 alpha significantly and consistently lowered monkey eye pressure, even in the untreated eye, while epinephrine had minimal effect. This highlights PGF2 alpha's potent and sustained IOP-lowering potential for glaucoma.
Abstract
After obtaining baseline intraocular pressure (IOP) measurements for 1 week, prostaglandin (PG) F2 alpha (250 micrograms in 50 microliters saline) or epinephrine 2% solution (50 microliters) was topically applied twice daily for 2 weeks to one eye of six cynomolgus monkeys for each agent tested. Contralateral control eyes received their respective vehicles. PGF2 alpha significantly reduced IOP beginning 2 to 3 hr after the first dose, persisting thereafter. A significant (P less than 0.05) hypotensive effect remained for at least 10 hr after the first dose and at least 14 hr after the sixth dose. At 4 hr after the seventh dose, the mean reduction was 10.2 +/- 3.5 (+/- SD) mmHg below baseline (P less than 0.0025). At this time, there was also a significant (P less than 0.01) mean reduction of IOP in the contralateral vehicle-treated eyes of 6.0 +/- 3.3 (+/- SD) mmHg below baseline, which did not appear to be secondary to diurnal fluctuations, repeated tonometry, experimental manipulation, or inadvertent drug transfer. Epinephrine significantly (P less than 0.05) reduced IOP beginning 3 hr after the first dose, but this reduction was minimal and not consistent. Neither PGF2 alpha nor epinephrine altered aqueous flow as measured by fluorophotometry 2 to 6 hr after the fifth dose. Outflow facility could not be assessed by indentation tonography because IOP was often too low at the time of measurement. Whereas PGF2 alpha did not alter pupil size, epinephrine caused significant pupillary dilation.(ABSTRACT TRUNCATED AT 250 WORDS)
MeSH Terms
Shields Classification
Related Articles5
Efficacy and mechanisms of intraocular pressure reduction with latanoprost and timolol in participants with ocular hypertension: a comparison of 1 and 6 weeks of treatment.
Randomized Controlled TrialUpdate on the mechanism of action of bimatoprost: a review and discussion of new evidence.
ReviewLatanoprost as a new horizon in the medical management of glaucoma.
ReviewEffects of latanoprost and dipivefrin, alone or combined, on intraocular pressure and on blood-aqueous barrier permeability.
Clinical TrialComparison of the intraocular pressure-lowering effect of latanoprost and timolol in patients with chronic angle closure glaucoma: a preliminary study.
Randomized Controlled TrialIs this article assigned to the wrong chapter(s)? Let us know.